文献速递甲状腺与颈部外科

骨改良药物可能改变原发性甲状旁腺功能亢进的生化表现与手术所见

Bone-modifying agents may alter biochemical presentation and operative findings in primary hyperparathyroidism.
PubMed 文献 · Surgery · 2026-09-01

本研究回顾性分析899例因原发性甲状旁腺功能亢进接受甲状旁腺切除术的患者,其中187例(20.8%)有骨改良药物使用史。骨改良药物使用者平均血钙(10.5 vs 10.9 mg/dL)和甲状旁腺激素(99.5 vs 119.7 pg/mL)水平更低,多腺体病变(43% vs 32%)和双侧颈部探查(54% vs 45%)更常见。

要点

  • 骨改良药物使用者血钙和PTH水平更低,可能掩盖典型生化表现。
  • 骨改良药物使用者多腺体病变比例更高(43% vs 32%),需警惕。
  • 该人群双侧颈部探查比例更高(54% vs 45%),术前规划应个体化。

核心结论

  • 骨改良药物使用与原发性甲状旁腺功能亢进患者独特的生化特征及更高多腺体病变患病率相关。

研究设计与样本

  • 单中心回顾性研究,纳入2019至2025年因原发性甲状旁腺功能亢进接受甲状旁腺切除术的899例患者。

主要发现

  • 骨改良药物使用者187例(20.8%),更可能为女性(P < .001)、白人(P < .001)且平均年龄更大(70 vs 60岁,P < .001)。
  • 骨改良药物使用者平均血清钙(10.5 vs 10.9 mg/dL,P < .001)和平均甲状旁腺激素(99.5 vs 119.7 pg/mL,P < .001)更低。
  • 骨改良药物使用者多腺体病变更常见(43% vs 32%,P = .03),双侧颈部探查更常见(54% vs 45%,P = .033)。

临床怎么用

  • 对计划接受甲状旁腺切除术的原发性甲状旁腺功能亢进患者,应询问骨改良药物使用史以辅助术前评估。
  • 骨改良药物使用者生化指标可能不典型,需警惕多腺体病变并个体化制定手术探查策略。

局限性

  • 回顾性单中心设计,仅行描述性统计和单变量分析,可能存在混杂偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Primary hyperparathyroidism is closely linked to bone metabolism, leading to increased bone resorption and osteoporosis. Bone-modifying agents are commonly used to mitigate bone loss by altering calcium metabolism; however, their effect on the biochemical and operative presentation of primary hyperparathyroidism has not been well characterized. This study evaluates the association between bone-modifying agent use, biochemical markers, and operative findings among patients with primary hyperparathyroidism. METHODS: A retrospective review was conducted of patients who underwent parathyroidectomy for primary hyperparathyroidism between 2019 and 2025 at a single tertiary referral center. A history of bone-modifying agent use and bone disease was assessed. Descriptive statistics and univariate analyses were performed to evaluate associations between bone-modifying agent use and the biochemical and operative phenotypes of primary hyperparathyroidism. RESULTS: A total of 899 patients met inclusion criteria, of whom 187 (20.8%) had a history of bone-modifying agent use. Patients with bone-modifying agent use were more likely to be female (P < .001), White (P < .001), and older on average (70 vs 60 years, P < .001). Mean serum calcium levels (10.5 vs 10.9 mg/dL, P < .001) and mean parathyroid hormone levels (99.5 vs 119.7 pg/mL, P < .001) were lower among bone-modifying agent users. Multigland disease was more frequent in bone-modifying agent users (43% vs 32%, P = .03) as was bilateral neck exploration (54% vs 45%, P = .033). CONCLUSION: In patients undergoing parathyroidectomy for primary hyperparathyroidism, the use of bone-modifying agents is associated with a distinct biochemical profile and a higher prevalence of multigland disease. A more nuanced understanding of the relationship between bone-modifying agents and the pathophysiology and surgical presentation of primary hyperparathyroidism could inform preoperative planning and guide individualized evaluation strategies in this patient population.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Chmiel AC, Giraldo G, Jones C, et al. Bone-modifying agents may alter biochemical presentation and operative findings in primary hyperparathyroidism. Surgery. 2026. PMID: 42791099. doi:10.1016/j.surg.2026.110587

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。